NASDAQ: ADXNAddex Therapeutics Ltd Stock
$8.07+0.25 (+3.2%)
Updated May 7, 2025
ADXN Price
$8.07
Fair Value Price
N/A
Market Cap
$6.35M
52 Week Low
$6.51
52 Week High
$13.27
P/E
144.11x
P/B
0.51x
P/S
11.49x
PEG
N/A
Dividend Yield
N/A
Revenue
$665.57k
Earnings
$6.36M
Gross Margin
100%
Operating Margin
946.32%
Profit Margin
912.4%
Debt to Equity
0.1
Operating Cash Flow
-$7M
Beta
0.43
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ADXN Overview
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ADXN's potential to beat the market
- ADXN doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ADXN
RankedUnranked of 461
RankedUnranked of 461
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.84 | A | |
| $40.76 | A | |
| $8.11 | A |
Be the first to know about important ADXN news, forecast changes, insider trades & much more!
ADXN News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ADXN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ADXN is poor value based on its earnings relative to its share price (144.11x), compared to the US market average (28.71x)
P/E vs Market Valuation
ADXN is good value based on its earnings relative to its share price (144.11x), compared to the US Biotechnology industry average (-161.89x)
P/E vs Industry Valuation
ADXN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more ADXN due diligence checks available for Premium users.
Valuation
ADXN fair value
Fair Value of ADXN stock based on Discounted Cash Flow (DCF)
Price
$8.07
Fair Value
-$0.11
Undervalued by
7,343.29%
ADXN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
144.11x
Industry
-161.89x
Market
28.71x
ADXN is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
ADXN is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
ADXN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.51x
Industry
4.19x
ADXN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ADXN's financial health
Profit margin
Revenue
$68.6k
Net Income
-$1.8M
Profit Margin
-2,622.2%
ADXN's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ADXN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$14.3M
Liabilities
$1.3M
Debt to equity
0.1
ADXN's short-term assets ($4.58M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ADXN's short-term assets ($4.58M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ADXN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$468.9k
Investing
-$6.9k
Financing
-$581.0
ADXN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ADXN vs Biotech Stocks
Addex Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.